| abstract |
REFERS TO A COMPOUND; OF FORMULA I; WHERE A IS -O-, -NH-; R1 IS H, C1-C7 ALCOXY, HALOGEN; R2 IS C2-C7 ALKYL, C1-C7 HALOGEN-ALKYL, BENZYL, AMONG OTHERS; R3 IS H, HYDROXY, C1-C7 ALCOXY, -O-C3-C7 CYCLOALKYL, AMONG OTHERS; R4 IS H, HYDROXY, AMINO, -O-BENZYL, AMONG OTHERS; R5 IS H, HALOGEN, C1-C7 ALCOXY; G IS G1, GE, AMONG OTHERS; R7 AND R11 ARE EACH H; R8 AND R10 ARE EACH H, O -NH-C (O) R25; R25 IS C1-C7 ALKYL; R9 IS H, C1-C7 ALKYL, HALOGEN, CYANE, AMONG OTHERS; R12 IS H, C1-C7 ALKYL, HALOGEN, AMINO; R13 IS H, C1-C7 HALOGEN-ALKYL, CYANE, NITRO, TETRAZOLYL, AMONG OTHERS; R14 IS C1-C7 ALCOXY, CYANE, CARBAMOYL, AMONG OTHERS; R15 IS H, CYANE, HALOGEN OR C1-C7 HALOGEN-ALKYL. PREFERRED COMPOUNDS ARE 4- [1- (3-ETOXY-4-METOXY-BENZYL) -PIPERIDIN-4-ILAMINO] -BENZONITRILEO, 4- [1- (3-ETOXI-4-METOXI-BENZYL) -PIPERIDIN-4- ILAMINO] -N- (5-METHYL-ISOXAZOL-3-IL) -BENZENOSULFONAMIDE; AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE. SUCH COMPOUNDS ARE USEFUL MODULATORS OF SSTR5 RECEPTOR ACTIVITY IN THE TREATMENT OR PREVENTION OF TYPE II DIABETES MELLITUS AND RELATED DISEASES SUCH AS MICROVASCULAR COMPLICATIONS |